Objective: A comparison of the effects of early (<2 h) and late (X2 h) discontinuation of prostaglandin E 1 (PGE 1 ), on systemic oxygenation following a successful balloon atrial septostomy (BAS), in neonates with confirmed diagnosis of d-transposition of the great arteries (d-TGA).
Introduction
Transposition of the great arteries (TGA) is the most common cyanotic heart defect that is present in the newborn babies. 1 Prior to the introduction of the Rashkind's balloon atrial septostomy (BAS) in 1966, mortality in the first month of life was approximately 50%. 2 BAS has resulted in a significant decrease in early mortality, but it has long been recognized that despite the creation of an adequate atrial septal defect (ASD) significant hypoxemia may recur following the procedure. 3 Intravenous prostaglandin E 1 (PGE 1 ) is standard of care in the early stabilization of neonates with profound hypoxemia and suspected TGA. The first studies to document a beneficial effect of PGE 1 treatment were conducted in neonates with persistent hypoxemia and metabolic acidosis despite a successful BAS. [4] [5] [6] [7] This perceived benefit is thought to be primarily as a result of increased ductal patency and enhanced pulmonary blood flow; however it could also be attributed to its direct vasodilator properties on the pulmonary vascular bed. 7 The optimal timing of discontinuation of PGE 1 infusion after a successful BAS remains unclear. First reports of the use of prostaglandin in this population suggest that it should be used for as short a period as possible in order to facilitate the normal reduction in pulmonary vascular resistance. 7 Therefore, clinically, early discontinuation is often thought to be preferable as it is believed to 'train' the left ventricle in preparation for its sudden exposure to the higher systemic vascular resistance postarterial switch procedure. The purpose of this study was to investigate the effects of prostaglandin discontinuation following a successful BAS in neonates with a postnatal diagnosis of TGA.
Methods

Primary objective
The aim of our study was to compare the effects of early (<2 h) vs late (X2 h) discontinuation of PGE 1 , in neonates with confirmed TGA post BAS. We hypothesized that early discontinuation of PGE 1 would be associated with an increased risk of critical rebound hypoxemia (Oxygen saturation (SpO 2 ) p65%) despite the creation of an adequate ASD.
Study design
Retrospective cohort study performed at an outborn quaternary neonatal intensive care unit (NICU).
Study population
All neonates with a two-dimensional echocardiography (2D echo) confirmed diagnosis of d-TGA, who required admission to the NICU, at the Hospital for Sick Children, between January 1999 and December 2004 were considered eligible. Neonates with an antenatal diagnosis, delivered in a high-risk perinatal center where PGE 1 was commenced at birth, were excluded.
Pre-hospital stabilization
All patients were retrieved by the Acute Care Transport Services (ACTS), which is a dedicated two-member neonatal transport team with back-up medical support. Patients in both groups were characterized according to relevant maternal and neonatal demographics, birth history, need for resuscitation, early postnatal course and need for cardiotropic support. A diagnosis of 'suspected' duct-dependent pulmonary blood flow lesion was made in neonates with hypoxemia where the clinical history and examination was more suggestive of congenital heart disease than persistent pulmonary hypertension of the newborn (PPHN). Intravenous PGE 1 was commenced for critical hypoxemia, but intubation was dependent on cardiorespiratory instability. The response to PGE 1 was determined by comparing pre-and postintervention SpO 2 levels.
Tertiary center stabilization
All 2D echo's on admission were reviewed to compare characteristics of the specific defect. In particular the presence of associated defects (for example, pulmonary stenosis, ventricular septal defect) and size of ASD were documented. Where necessary, BAS was performed as soon as possible, following admission. All neonates were intubated prior to septostomy, receiving between 21 and 100% oxygen. Details of the success of the procedure as judged by the size of the ASD and change in SpO 2 were compared. A successful BAS was defined by an appropriately sized ASD, as determined echocardiographically by the attending cardiologist, which resulted in adequate intratrial mixing with in increase in preductal SpO 2 to >75%. Oxygen treatment was titrated slowly to maintain the SpO 2 between 75 and 85%. The timing of PGE 1 discontinuation was dependent on the physician's (pediatric cardiologist) preferences as there was no standard BAS protocol at the time of this review. We chose 2-h as an arbitrary definition of early discontinuation as it best reflected the time from 'making the decision' to actual termination of the infusion by the neonatal team. The outcome of this decision was judged according to changes in SpO 2 and FiO 2 , need for recommencement of PGE 1 and maximum dose achieved, age at surgery and postoperative outcomes. Mean SpO 2 was recorded at the following time points; before and after initial PGE1 commencement and before and 1 h after BAS. The frequency of critical hypoxemia in both groups was reviewed. Postoperative outcome measures included the onset of cardiac arrhythmias requiring therapeutic intervention, duration of mechanical ventilation, presence of abnormal finding on cranial ultrasound (defined as white matter injury or IVH Xgrade 2). In an effort to provide a quantified index of the patient's condition, the dosages of cardiotropic infusions before arrest were used to derive a cardiotrope score, similar to previous descriptions. 8 The score was obtained with the formula,
, using dosages which are expressed in micrograms per kilogram per minute. The arterial switch procedure was performed in all cases according to published reports. 9 Statistical analysis Neonatal data were characterized using descriptive statistics where appropriate (for example, mean ( ± s.d.) and median (range) for continuous variables and frequency for categorical variables). Between-group comparisons of SpO 2 and FiO 2 were analyzed using Student's t-tests and Mann-Whitney U test for respective parametric and nonparametric datasets. Fisher's exact test or w 2 analysis was used for categorical variable (for example, need for reinstitution of PGE 1 or need for postoperative cardiotropic support). Two-way analysis of variance (ANOVA) was used to compare the effects of time and within-or between-group differences in SpO 2 (post hoc Student-Newman-Keuls method) in babies who required recommencement in PGE 1 and those who did not, for both the early and late groups, respectively. Level of significance was set at P-value <0.05.
Results
In total, 60 neonates with a diagnosis of d-TGA were identified over the study period ( Figure 1 ). The mean gestation and weight at birth were 38.2±2.8 weeks and 3216±804 g, respectively. Fiftyfour of these infants received PGE 1 for initial stabilization and in 45 cases a successful BAS was performed. In six babies PGE 1 was not used for stabilization as a ventricular septal defect (VSD) or large ASD enabled adequate mixing and acceptable oxygenation. Following the BAS, 25 neonates had early discontinuation of the PGE1 infusion whereas in the remaining 20 cases late discontinuation occurred. The median times of PGE1 discontinuation were 0.1 h (0.1 to 1.9) and 9 h (2.5 to 120) in the early and late groups, respectively. There were no differences in baseline neonatal demographics, characteristics of the cardiac diagnosis or age at clinical presentation, age at commencement and dose of intravenous PGE 1 between both groups (Tables 1  and 2 ). In addition, there were no differences in the use of cardiotropic drugs or inhaled nitric oxide (iNO) during the initial stabilization period or in the success of the BAS ( Table 2 ). Administration of PGE 1 was associated with a significant improvement in SpO 2 over time (Figure 2 , ANOVA P<0.05). BAS was followed by a significant decrease in oxygen requirement in both groups (P<0.05), although the post-BAS oxygen requirement was significantly higher in the late group (Figure 3, P<0.05 ). There was no difference in the magnitude of the reduction in FiO 2 between the early (20.4%±31.9) and late (16.8%±24.1) groups, respectively. In 20 neonates (20/45 (44%)), the PGE 1 infusion was recommenced for rebound hypoxemia despite a successful BAS. Of these, there was a threefold increase in the need for reinstitution of prostaglandin in the early compared to the late group (16/25 (64%) vs 4/20 (20%), P<0.006). There was no difference in time of PGE 1 discontinuation between those requiring recommencement of treatment in either group (Figure 4) although there was no case of rebound hypoxemia requiring recommencement of treatment if PGE 1 were discontinued after 24 h. There was a trend toward higher rate of pre-BAS cardiotropic support in the early group compared to late group (6/8 (75%) vs 2/10 (20%), P ¼ 0.06). Recommencement of PGE 1 was associated with an improvement in SpO 2 in both the early (ERC) and late recommencement (LRC) groups, respectively (Figure 3 ; ANOVA P<0.05). There was no overall difference in mean SpO 2 between the ERC and LRC groups (71.7 ± 1.3% vs 70% ± 2.0, ANOVA P ¼ 0.47) or between the early (ENRC) and late nonrecommencement (LNRC) groups (80.4% ± 1.7 vs 76.5% ± 1.4, ANOVA, P ¼ 0.1), respectively. Mean SpO 2 was significantly lower in the ERC (ANOVA, P<0.001) and LRC (ANOVA, P<0.05) groups, respectively, compared to both groups not requiring recommencement of PGE 1 . The duration of PGE 1 after recommencement did not differ between the early and late groups (16 h (1.7 to 120) vs 16 h (3 to 120), P ¼ 0.79), respectively. Postoperatively, there was no difference in indices of cardiorespiratory stability, such as ventilator days and cardiotropic scores, or other morbidities between the groups (Table 3) . Prostaglandin treatment following balloon atrial septostomy E Finan et al the effects of early sustained postnatal hypoxemia on a labile pulmonary vascular bed, thus limiting the normal postnatal fall in pulmonary artery pressure. As PGE 1 is known to have vasodilator properties, sudden discontinuation may lead to increased pulmonary vascular resistance (PVR) and decreased pulmonary blood flow. It has long been recognized that in a number of patients, hypoxemia does recur despite the creation of an adequate ASD after BAS. 3, 4, 7 In the late 1970s, first reports in the use of PGE 1 were in this population of babies, who were noted to have improved oxygenation, with less acidosis, following the commencement of prostaglandin. [3] [4] [5] 7, 10 This improvement was thought to be a result of improved ductal patency but also possibly due to a decrease in pulmonary vascular resistance, enabling increased pulmonary blood flow. The benefit from ongoing PGE 1 treatment may also reflect the need to keep the ductus patent and maintain a higher left atrial pressure, when there is right ventricular dysfunction, in order to sustain adequate transatrial mixing. The trend toward a higher rate of rebound hypoxemia in neonates who required cardiotropic support before BAS in our study suggests this may indeed be the case. Unfortunately serial echocardiography was not routinely performed to characterize cardiovascular physiology after PGE 1 withdrawal and recommencement.
The aim of our study therefore was to investigate the effect of time of PGE 1 discontinuation on oxygen saturations, oxygen requirements and the subsequent need for reinstitution of PGE 1 treatment. Both groups were comparable in terms of the clinical presentation or illness severity, anatomic characteristics of the cardiac defect, early stabilization and response to BAS. This renders time of PGE 1 discontinuation as the only significant difference between the groups. We speculate that the mechanism of the rebound hypoxemia is related to altered pulmonary vasoreactivity. It is well recognized that hypoxia induces potent pulmonary vasoconstriction which may result in a failure of the normal postnatal fall in pulmonary vascular resistance. 11 In our study the mean age at transfer was 27 h and oxygen saturations on admission were approximately 60%. This is in keeping with previous work demonstrating that 50% of infants with TGA arrived at the receiving center with saturations <60%. 12 The effects of sustained hypoxemia on pulmonary vascular resistance and pulmonary arterial pressures are poorly understood. More recent literature does suggest an association between TGA and pulmonary hypertension. Soongswang et al. 13 in an 8-year review of TGA patients demonstrated a preoperative mortality rate of 4.1% (12/295), of which 16.7% was related to pulmonary hypertension. This association has been supported by studies showing improved stability in extremely hypoxemic infants with the use of iNO. 14, 15 Premature closure of the foramen ovale and/or ductus arteriosus also has been shown to be associated with severe postnatal hypoxemia [16] [17] [18] and pulmonary hypertension, thought to occur as a result of pulmonary vascular remodeling. 18 The rationale to discontinue the PGE 1 infusion is based on a theoretical risk that if the left ventricle (LV) is exposed to a lower PVR preoperatively, it is less likely to adapt to the sudden increase in LV afterload that occurs following the arterial switch procedure. We did not identify an obvious increased risk of cardiorespiratory stability as judged by the duration of assisted ventilation, need for cardiotropic support or frequency of cardiac dysrhythmias. In fact, early discontinuation of the PGE 1 infusion led to an overall increase in the duration of preoperative exposure in those cases where the infusion was recommenced.
The rebound hypoxemia that occurs on discontinuation on PGE 1 is concerning, given the strong relationship between hypoxemia and adverse neurodevelopmental outcomes in several recent studies. Galli et al. 19 have shown the presence of periventricular white matter changes on MRI in 54% of neonates who underwent cardiopulmonary bypass for repair of congenital heart disease and have identified both arterial PaO 2 and diastolic blood pressure to be independent risk factors for this abnormal outcome. Hovels-Gurich et al. 20 have also shown preoperative hypoxemia to be associated with an increased risk of motor dysfunction in long-term follow up. Toet et al. 21 studied cerebral oxygen saturation in term infants undergoing the arterial switch procedure. Specifically, they demonstrated that babies with lower preoperative cerebral oxygen saturation tended to have a lower developmental quotient at 30 to 36 months. Babies undergoing cardiopulmonary bypass showed a decrease in cerebral oxygen saturation, which normalized by 6 to 26 h; however, lower saturation preoperatively was one of the factors associated with a longer recovery time. These studies emphasize the adverse consequences of suboptimal cerebral oxygen delivery.
This study has some limitations. First, as the study is retrospective and the sample size is small it is possible that there may be other confounding factors that may influence the occurrence of critical hypoxemia. The definition of a successful BAS is subject to variability between physicians performing the procedure although in all cases there was immediate improvement in SpO 2 . The magnitude of the transatrial or transductal shunts are difficult to quantify echocardiographically, however differences in blood mixing may potentially explain the differences in systemic oxygen levels seen. The increased need for PGE 1 recommencement in the early group is unlikely to be related to the success of BAS or illness severity, as overall post-BAS oxygen requirements were lower in these babies. Unfortunately we do no have direct measurements of PVR to support our hypothesis. Nevertheless the magnitude of the response to PGE 1 recommencement emphasizes the need for a prospective randomized trial to investigate the hypothesis. Finally, this study is predominantly composed of babies with TGA with a postnatal diagnosis, therefore these conclusions are probably not applicable to neonates diagnosed antenatally, where PGE 1 is normally commenced immediately at birth and there is no prolonged period of hypoxemia.
In summary, early discontinuation of intravenous PGE 1 treatment following BAS in neonates with TGA is associated with an increased risk of rebound hypoxemia, necessitating the recommencement of PGE 1 . We speculate that rapid improvement in oxygenation on reinstitution of PGE 1 is secondary to pulmonary vasodilation and improved pulmonary blood flow. The benefits may also suggest the need to maintain ductal patency and a high left atrial pressure in some patients in order to support transatrial mixing. We propose a more cautious approach to discontinuation based on illness severity, need for cardiotropic support and the magnitude of hypoxemia, where PGE 1 is weaned slowly and titrated according to changes in oxygenation.
